GSK GSK
Company Profile ↓Company Overview
GSK (GSK) is a publicly traded company listed on with a market capitalization of $222.07B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 34.9%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.0%.
Maintains a net profit margin of 17.5%.
Recent Developments
- Dec 2025 Revenue of $32.67B (+4.1% YoY); net profit $5.72B.
- Trailing 12 Months Year-on-year growth — revenue +4.1%, earnings +122.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.7%, profit CAGR -27.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.66% |
| 1 Year: | 4.11% |
Compounded Profit Growth
| 5 Years: | -27.43% |
| 1 Year: | 121.98% |
Stock Price Performance
| 1 Year: | +41.69% |
| 6 Months: | -1.86% |
| 3 Months: | +3.08% |
| 1 Month: | -3.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 34.9%.
- Healthy ROCE of 21.0%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -27.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 7.99B | 8.55B | 8.62B | 7.63B | 8.41B |
| Cost of Revenue | - | - | 2.17B | 2.26B | 2.66B | 1.88B | 2.27B |
| Gross Profit | - | - | 5.82B | 6.29B | 5.96B | 5.75B | 6.14B |
| Operating Expenses | - | - | 3.80B | 3.70B | 4.46B | 3.46B | 5.66B |
| Operating Income | - | - | 2.02B | 2.59B | 1.51B | 2.29B | 481.00M |
| EBITDA | - | - | 3.23B | 3.36B | 1.12B | 2.77B | 2.83B |
| Interest Expense | - | - | 184.00M | 167.00M | 174.00M | 167.00M | 182.00M |
| Pretax Income | - | - | 1.89B | 2.46B | 950.00M | 2.14B | 354.00M |
| Tax Provision | - | - | 241.00M | 312.00M | 223.00M | 305.00M | -199.00M |
| Net Income | - | - | 1.44B | 2.01B | 636.00M | 1.74B | 435.00M |
| Diluted EPS | - | - | 0.70 | 0.98 | 0.31 | 0.85 | 0.21 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 29.32B | 30.33B | 31.38B | 32.67B |
| Cost of Revenue | - | 9.55B | 8.56B | 9.05B | 9.02B |
| Gross Profit | - | 19.77B | 21.76B | 22.33B | 23.65B |
| Operating Expenses | - | 13.04B | 14.42B | 16.79B | 15.31B |
| Operating Income | - | 6.73B | 7.34B | 5.54B | 8.34B |
| EBITDA | - | 8.60B | 9.08B | 6.67B | 10.40B |
| Interest Expense | - | 826.00M | 725.00M | 640.00M | 687.00M |
| Pretax Income | - | 5.63B | 6.06B | 3.48B | 7.40B |
| Tax Provision | - | 707.00M | 756.00M | 526.00M | 1.11B |
| Net Income | - | 14.96B | 4.93B | 2.58B | 5.72B |
| Diluted EPS | - | 7.32 | 2.40 | 1.24 | 2.78 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 60.15B | 59.01B | 59.46B | 61.12B |
| Current Assets | - | 20.77B | 18.64B | 17.00B | 17.51B |
| Cash & Equivalents | - | 3.52B | 2.75B | 3.69B | 3.15B |
| Inventory | - | 5.15B | 5.50B | 5.67B | 5.92B |
| Receivables | - | 5.45B | 5.91B | 5.56B | 5.91B |
| Total Liabilities | - | 50.05B | 46.21B | 46.38B | 45.16B |
| Current Liabilities | - | 22.81B | 21.07B | 21.70B | 21.39B |
| Long Term Debt | - | 16.19B | 14.15B | 13.70B | 14.02B |
| Total Debt | - | 20.99B | 18.02B | 16.99B | 17.72B |
| Total Equity | - | 10.60B | 13.35B | 13.67B | 16.38B |
| Shares Outstanding | - | 4.31B | 4.31B | 4.31B | 4.32B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 67.4% | 71.8% | 71.2% | 72.4% |
| Operating Margin % | - | 22.9% | 24.2% | 17.7% | 25.5% |
| Net Margin % | - | 51.0% | 16.2% | 8.2% | 17.5% |
| ROE % | - | 141.1% | 36.9% | 18.8% | 34.9% |
| ROCE % | - | 18.0% | 19.4% | 14.7% | 21.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GSK
GSK shares rise as $2.5B cost-cutting plan unveiled - BioSpace
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPMEhUWTlPZFJwWTNTOG5UMVdmdVlfUVl6U3h4dEtWM21SY1lPUDNxenlWWXJEdmpaaFRiZTA5UnNEenpDTE5WVnVTNkQ0aGRBSE5QUnNvUjNGcXpxb0YtV0VpOVhpMFZ4a2dUaWFyNzMtNzNONEFEOVRWMkwySXNXcmZvbi1XdjhDTUpBOQ…
GSK: Is This FTSE 100 Pharma Stock Making a Comeback? - Morningstar
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNUGVWNXdwdktQTDItTlFIdTBjb2tlQ05XeUJMaW1oUl9haHVZTXNjSGt2N0VtcW42dmJuUDNvNlY5N2lLN2VSbmlyWjZvZW9CNUJLZ3BROHY0cGVIQWJMSGplNVRXd2ZqVURTYVhzcS1ONVEtRHJVdU5wUmJPSElmaUMzM04zWmtlT0h5en…
GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs - Reuters
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPVEczNGtwNjlyMERkWXlkcVRKckpWU1pBa25VTHQyN0hNS2lYTHBoSHktMXRJMlU3VWU4QTNNanJ5b09jb0dWOXhYeFdkNlNBVEFxY1ZJNFRVMVFGZDlNVldjV3draUFOc1R2X2Qwdm50dHVRd3FIX3p2OWZhUk82aUNoTGlBSTY2MHJtSz…
By mid-2027, analysts expect £6,000 in GSK shares to be worth… - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOSDhsWDdQdm9odDhXZVJZTW5PVV80QWhYc3JuclVseWdxRTZibUlmWlg4NmFfV0J2Z0VhUW5SWkJOdXcycnJDVDQ2ckVibVBTbWM1eVlXdWduY1podHFMUVZxN0dkSEx4cUV5S1dPS2pFd1FiUXAtSV9JVlNsbllWLQ?oc=5" target="_…
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment - WSJ
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZkJxR19LQWN4eDU1Y21DSFQyZklha0dJV1huX3ZxWWxZQnhkTTJRbUo3Zl9uZTNQc0U3Z3ZwbWd3UDVhTFdyc3QwdVByeFgzdzJkUkk5TUJRWHl1WEotcC0yT1hxNzJIOGpOalVQNmhuQ0NrSnRKSUZJa1B4X013RUwwTjV1anBfNTRDTH…
GSK enters agreement to acquire Nuvalent, Inc. - GSK US
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPTTc3SFlzWjNlX0Q2b0xBdnl5N1kzazBFeG9UWUF3YVVRTjR0VEIxY200Wk85QXdUUnhwVFdVV0hJYmpHcUFoTzVZdExfRUlIM0FxM1ZCQVZTQjEtOGoxZFFEdldJMTNPMExRbFBUR3dqdnJXa2pSWC1tMmtReWZpSndMaUJCMlU1a254V0…
GSK — Frequently Asked Questions
What is the current share price of GSK?
As of 2026-08-05 17:25 PDT, GSK trades at $51.46 on NASDAQ/NYSE. Its 52-week range is $35.42 to $60.14.
What is the market capitalisation of GSK?
GSK has a market capitalisation of $222.07B on NASDAQ/NYSE.
What is the P/E ratio of GSK?
GSK trades at a trailing price-to-earnings (P/E) ratio of 18.54. Its price-to-book (P/B) ratio is 13.56.
What is the return on equity (ROE) of GSK?
GSK has a return on equity (ROE) of 34.90%. Its return on capital employed (ROCE) is 20.99%.
Is GSK a good stock to buy?
This page provides a data-driven analysis of GSK, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.